Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  voriconazole
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-10 of 10 for your search:
Start Over
Antifungal Prophylaxis in Pediatric Acute Leukemia
Phase: Phase III
Type: Supportive care
Status: Active
Age: 15 and younger
Sponsor: Other
Protocol IDs: antifungal prophylaxis, Dr. SAMEER BAKHSHI, NCT00624143
Pharmacologic Optimization of Voriconazole
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: VORI911, NCT00893555
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
Phase: Phase III
Type: Supportive care
Status: Active
Age: 3 months to 20 years
Sponsor: NCI, Other
Protocol IDs: ACCL1131, NCI-2012-00102, CDR0000721415, COG-ACCL1131, U10CA095861, NCT01503515
A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069/P06200)
Phase: Phase III
Type: Supportive care
Status: Active
Age: 13 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P06200, 2011-003938-14, 5592-069, NCT01782131
Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101)
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 5592-101, 142639, NCT02180165
Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection
Phase: Phase II
Type: Supportive care
Status: Active
Age: 18 to 55
Sponsor: Other
Protocol IDs: RJH-2011-71, NCT01501708
Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR106609, PCI-32765LYM1003, NCT02381080
Therapeutic Drug Monitoring (TDM) of Voriconazole and Correlation With CYP2C19 Genotype in Korean Populations
Phase: No phase specified
Type: Supportive care
Status: Active
Age: 15 to 65
Sponsor: Other
Protocol IDs: VCZ_TDM_Korea, NCT00673348
CYP 2C19 Polymorphism and Voriconazole Trough Concentration in Chinese Adult Patients
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: KYLL-2014(KS)-085, NCT02100761
Concentrations of Voriconazole in Blood and BAL-fluid After Inhalation and Oral Administration
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: M-2013-242-13, NCT02396225
Start Over